Clinical Trial Update: Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab [Phase 4]

View source ↗

Summary

A Phase 4 prospective study update examining disease activity and biomarkers in minority participants with relapsing multiple sclerosis treated with ocrelizumab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Sclerosis, Relapsing | Phase 4 | Status: COMPLETED